REVIEW ON: A MECHANISM ACTION OF FAVIPIRAVIR(T-705) AGAINST TARGETAL VIRAL RNA POLYMERASE
Rushikesh B. Shinde* and Gaurav D. Borse
Favipiravir is a pyrazine carboxamide derivative (6‐fluoro‐3‐hydroxypyrazine‐2-carboxamide) and a broad‐spectrum antiviral drug approved by the Drug Controller General of India (DCGI) an antiviral drug commonly used for treating influenza for the treatment of mild to moderate cases of COVID-19 in India. Favipiravir is a prodrug that is metabolized in cell to active form favipiravir-ribosyl triphosphate (favipiravir RTP). When drug enters it gets mostly metabolized by aldehyde oxidase (AO) which it forms inactive metabolite(T-705M1) and partly hydroxylate form by xanthine oxidase (XO), further favipiravir RTP active form which binds to RNA dependent RNA polymerase (RdRp) and inhibit the viral replication. Here we discuss about mechanism of action of favipiravir to targeted viral RNA polymerase as well as their adverse effect to other body organs.
Keywords: Favipiravir, Mechanism of action, Adverse effect.
[Full Text Article]